Preterm Drug's hidden impact? 6-Year study on Kids' brains begins
NCT ID NCT07146451
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study follows 480 children born to mothers who received either nifedipine or a placebo after early rupture of membranes (22-33 weeks). Researchers will assess the children at age 6 for cerebral palsy, coordination, language, behavior, and thinking skills using parent questionnaires and online tests. The goal is to see if nifedipine exposure before birth has any long-term effects on neurodevelopment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
nifedipine
What this could lead to
If successful, this could show whether nifedipine is safe for children's long-term brain development after preterm birth.
What could go wrong
This is an observational follow-up, not a new treatment test. Results depend on parent reports and may not prove cause and effect.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHILDREN BORN TO MOTHERS ENROLLED IN THE TOCOPROM TRIAL are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Trousseau University Hospital
RECRUITINGParis, France, 75012, France
Contact Phone: •••-•••-•••• Email: •••••@•••••